AnOpen-label, Multicenter, Phase 3 Randomized, Active-Comparator-ControlledClinical Study of Pembrolizumab (MK-3475) in Combination With SacituzumabGovitecan Versus MK-3475 Monotherapy as First-line Treatment in ParticipantsWith PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell LungCancer (KEYNOTED46/EVOKE-03)

KEYNOTE D46/EVOKE-03 - MK-3475-D46

Comprehensive Cancer Center Mainfranken

Lungentumoren

Nicht-kleinzelliges Bronchialkarzinom (NSCLC)

PD-1 (Programmed cell death protein 1)

PD-L1

Phase III

Herr Dr. Jens Kern

Herr Dr. Harald Rosenberger

Frau Christiane Köhler

Innere Medizin

Klinikum Würzburg Mitte gGmbH (Standort Missioklinik)

Erstlinie

Therapeutisch